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Blood Sampling and Biochemical Analysis  
On follow-up, non-fasting samples of venous blood were drawn, put on ice and processed 
within 60 minutes. EDTA-plasma specimens were centrifuged at 13 500 and serum specimens 
at 3500 relative centrifugal force for 30 minutes; the clear supernatants were then transferred 
to the sample cups and stored at -80°C. Before analysis, thawed specimens were mixed 
thoroughly by low-speed vortexing until visibly homogeneity.  
 
Serum cardiac troponin I (cTnI) on follow-up was measured by STAT High Sensitive 
Troponin-I assay on an Alinity platform (Abbott Diagnostics, Abbott, IL). The level of blank 
was 1.0 ng/L and the level of detection 1.6 ng/L. Concentrations below or equal to the level of 
blank were assigned a value of 1.0, whereas levels below or equal to the level of detection and 
greater than the level of blank, were assigned a value of 1.6 ng/L. At baseline and during 
adjuvant therapy, cTnI was measured by STAT High Sensitive Troponin-I assay on an 
Architect i2000SR platform (Abbott Diagnostics, Abbott, IL). For this assay level of blank 0.8 
ng/L and the level of detection 1.2 ng/L, concentrations below or equal to the limit of blank 
were assigned a value of 0.8 ng/L, whereas levels below or equal to the limit of detection and 
greater than the limit of blank were assigned a value of 1.2 ng/L. 
 
Serum cTnT on follow-up was measured by a high-sensitivity assay (Troponin T hs STAT) 
on a cobas 8000 e602 analyzer (Roche Diagnostics, Rotkreuz, Switzerland). The level of 
blank was 2.5 ng/L and the level of detection 3 ng/L. Values equal to or below 3.0 ng/L were 
assigned a value of 3.0. At baseline and during adjuvant therapy, cTnT was measured with 
cobas 8000 e602 analyzer (Roche Diagnostics, Rotkreuz, Switzerland). The level of blank 
was 3.0 ng/L and the level of detection 5 ng/L. Concentrations below or equal to the limit of 
blank were assigned a value of 3.0 ng/L, whereas levels below or equal to the limit of 
detection and greater than the limit of blank were assigned a value of 5 ng/L. N-terminal pro 
B-type natriuretic peptide (NT-proBNP) in serum was on follow-up measured by the proBNP 
II assay on a cobas 8000 e801 analyzer (Roche Diagnostics, Rotkreuz, Switzerland). The 
analytical measurement range is 5 to 35 000 pg/mL. At baseline and during adjuvant therapy, 
NT-proBNP was measured with cobas 8000 e602 analyzer (Roche Diagnostics, Rotkreuz, 
Switzerland) where the analytical range was 5 to 35 000 pg/mL.  
  
344 assessed for eligibility
130 enrolled and randomized
214 ineligible
146 did not meet the inclusion criteria
27 declined to participate 
41 other reasons
32 allocated to candesartan-metoprolol 33 allocated to candesartan-placebo 32 allocated to metoprolol-placebo 33 allocated to placebo-placebo
2 excluded due to non-
compliance
22 included in per-protocol analysis
1 excluded after 
discovering of previous 
radiation therapy
1 did not receive 
chemotherapy as 
planned




1 excluded due to not 
receiving chemotherapy 
as planned
2 excluded due to non-
compliance
2 excluded due to non-
compliance
2 excluded due to 
missing baseline CMR
2 excluded due to 
missing baseline CMR
4 excluded due to 
missing follow-up 
CMR
4 excluded due to 
missing follow-up 
CMR
7 excluded due to 
missing follow-up 
CMR
2 excluded due to 
missing follow-up 
CMR
2 excluded due to 
missing baseline CMR
2 excluded due to non-
compliance
28 included in per-protocol analysis 24 included in per-protocol analysis 21 included in per-protocol analysis
Supplemental Figure I Per-protocol consort diagram
Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): screening and 
randomization. The per-protocol analysis was performed on all compliant, validly randomized 




Supplemental Table I  
Eligibility criteria  
 
Inclusion criteria 
Women aged 18-70 years 
Eastern Cooperative Oncology Group (ECOG) performance status 0–1 
Serum creatinine < 1.6 mg/dL or estimated glomerular filtration rate (eGFR) ≥ 60 
ml/min/1.73 m2 
Systolic blood pressure ≥ 110 mg Hg and < 170 mm Hg 
Left ventricular ejection fraction ≥ 50% 
 
Exclusion criteria 
Hypotension, defined as systolic blood pressure < 110 mmHg 
Prior anthracycline chemotherapy regimen 
Prior malignancy requiring chemotherapy or radiotherapy 
Symptomatic heart failure 
Systolic dysfunction (left ventricular ejection fraction < 50%) 
Clinically significant coronary artery disease, valvular heart disease, significant arrhythmias, 
or conduction delays 
Bradycardia, defined as heart rate < 50 b.p.m. 
Uncontrolled arterial hypertension defined as systolic blood pressure > 170 mm Hg 
Treatment with angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or 
beta-blocker within the last 4 weeks prior to study start 
Intolerance to angiotensin-converting enzyme inhibitor, angiotensin receptor blocker or beta-
blocker 
Uncontrolled concomitant serious illness, as determined by the investigator  
Pregnancy or breastfeeding 
Active abuse of drugs or alcohol 
Suspected poor compliance 




Supplemental Table II Tumor characteristics    










N 28 32 30 30 
Mastectomy 8 (28.6%) 8 (25.0%) 14 (46.7%) 15 (50.0%) 
Right Side 16 (57.1%) 16 (50.0%) 18 (60.0%) 16 (53.3%) 
Left side 11 (39.3%) 16 (50.0%) 10 (33.3%) 145 (46.7%) 
Bilateral 1 (3.6%) 0 (0%) 2 (6.7%) 0 (0%) 
Tumor size:          
Tumor not found 0 (0.0%) 2 (6.3%) 0 (0%) 0 (0%) 
T1 14 (50.0%) 17 (53.1%) 15 (50.0%) 12 (40.0%) 
T2 14 (50.0%) 12 (37.5%) 15 (50.0%) 17 (56.7%) 
T3 0 (0%) 1 (3.1%) 0 (0%) 1 (3.3%) 
Tumor grade          
G0 0 (0%) 1 (3.1%) 0 (0%) 0 (0%) 
G1 0 (0%) 2 (6.3%) 0 (0%) 1 (3.3%) 
G2 12 (42.9%) 11 (34.4%) 14 (46.7%) 9 (30.0%) 
G3 16 (57.1%) 18 (56.3%) 16 (53.3%) 20 (66.7%) 
Lymph node         
N0 16 (57.1%) 20 (62.5%) 17 (56.7%) 17 (56.7%) 
N1 10 (35.7%) 7 (21.9%) 7 (23.3%) 9 (30.0%) 
N2  2 (7.1%) 5 (15.6%) 5 (16.7%) 2 (6.7%) 
N3 0 (0%) 0 (0%) 1 (3.3%) 2 (6.7%) 
Immunohistology         
HER 2 positive* 7 (25.0%) 7 (21.9%) 6 (20.0%) 8 (26.7%) 
Estrogen Receptor negative (< 1%) 7 (25.0%) 8 (25.0%) 6 (20.0%) 10 (33.3%) 
Estrogen Receptor positive >1% and <50% 1 (3.6%) 0 (0%) 3 (10.0%) 2 (6.7%) 
Estrogen Receptor positive ≥50% 20 (71.4%) 24 (75%) 21 (70.0%) 18 (60.0%) 
Progesterone Receptor positive (>10%) 16 (57.1%) 20 (62.5%) 16 (53.3%) 19 (63.3%) 
Ki 67 ≥ 30 % 16 (57.1%) 22 (68.8%) 17 (56.7%) 17 (56.7%) 
Ki 67 < 30% 3 (10.7%) 7 (21.9%) 9 (30.0%) 7 (23.3%) 
Not measured 9 (32.1%) 3 (9.4%) 4 (13.3%) 6 (20.0%) 
Treatment         
FEC† 240 mg/m² (161 mg/m² DE‡) 17 (60.7%) 19 (59.4%) 17 (56.7%) 15 (50.0%) 
FEC 360 mg/m² (241 mg/m² DE) 4 (14.3%) 6 (18.8%) 6 (16.7%) 6 (20.0%) 
FEC 400 mg/m² (268 mg/m2 DE)  7 (25.0%) 7 (21.9%) 6 (20.0%) 7 (23.3%) 
Incomplete FEC treatment 0 (0%) 0 (0%) 2 (6.7%) 2 (6.7%) 
Trastuzumab 7 (25.0%) 7 (21.9%) 6 (20.0%) 7 (23.3%) 
Incomplete Trastuzumab 0 (0%) 0 (0%) 1 (3.3%) 0 (0%) 
Taxol 21 (75.0%) 22 (68.8%) 21 (70.0%) 15 (50.0%) 
Taxotere 1 (3.6%) 1 (3.1%) 2 (6.7%) 4 (13.3%) 
Incomplete Taxane treatment 2 (7.1%) 2 (6.3%) 2 (6.7%) 3 (10.0%) 
Radiation 16 (67.1%) 19 (59.4%) 20 (66.7%) 21 (70.0%) 
Left side  4/16 (25.0%) 11/19 (57.9%) 6/20 (30.0%) 7/21 (33.3%) 
Right side 12/16 (75.0%) 8/19 (42.1%) 14/20 (70.0%) 14/21 (66.7%) 
* HER 2 positive denotes immunohistochemistry (IHC) 3+ or IHC 2+ and amplified (ISH)  
† FEC: fluorouracil, epirubicin, cyclophosphamide. Accumulated epirubicin dose. There were no significant 
  differences between the four study groups  
‡ DE: Doxorubicin equivalents  
 
